



6 March 2025

ASX Announcement

SHAREHOLDER TOWN HALL WEBINAR

InhaleRx Ltd (ASX: IRX), (“**InhaleRx**”, “**IRX**” ‘or “**the Company**”) an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, is pleased to invite shareholders and interested potential investors to a webinar on Thursday, 13 March 2025, commencing at 4.00pm AEDT.

The webinar will be led by the Company’s CEO, Darryl Davies, and Medical Advisor, Dr Sud Agarwal, who will provide an update on recent developments and the Company’s progress in its clinical development program.

To access the webinar, please use the following link:

https://us02web.zoom.us/webinar/register/WN_tZuvU3iBT2eWAtvyICZhXA

Interested attendees are encouraged to email any specific questions they would like addressed by 5pm AEDT on Tuesday, 11 March 2025 to: info@inhalerx.com.au

A copy of the presentation slides for the webinar will be lodged on the ASX immediately prior to the webinar commencing.

Authorised by the Board of Directors.

For further information:

James Barrie
Company Secretary
Phone +61 3 8678 4091
info@inhalerx.com.au
www.inhalerx.com.au

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders, the first medical indications under investigation and Breakthrough Cancer Pain ('**BTcP**') and Panic Disorder ('**PD**'), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.